DOJ and Lincoln Pharmacy in Tacoma Settle Allegations the Pharmacy Failed to Follow the Controlled Substances Act
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Domestic Divisions
      • Foreign Divisions
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Forensic Sciences
      • GUARDS
      • Forensic Sciences Policy
      • Forensic Science Organizations
      • Forensic Science Contact
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
    • Education and Prevention
      • Family Summit
      • Red Ribbon
      • Kiki and the History of Red Ribbon Week
      • Red Ribbon Toolkit - Resources For Your Community
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Senior Citizens
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
      • Operation Warfighter
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • DOJ and Lincoln Pharmacy in Tacoma Settle Allegations the Pharmacy Failed to Follow the Controlled Substances Act

DOJ and Lincoln Pharmacy in Tacoma Settle Allegations the Pharmacy Failed to Follow the Controlled Substances Act

February 28, 2023
|
Share Article
|
Download Press Release
For Immediate Release
Contact:
Phone Number: (571) 387-3831

Settlement is One of Three Related to DEA Civil Investigations

SEATTLE – The U.S. Attorney’s Office and Lincoln Pharmacy in Tacoma have reached a settlement agreement over inspection findings by the Drug Enforcement Administration that Lincoln had failed to comply with some of the administrative requirements of the Controlled Substances Act (CSA). Lincoln Pharmacy will pay the United States $80,000 to resolve the claims. The settlement is one in a series of enforcement actions the DEA has taken with providers and pharmacies over administrative violations of the CSA.

“The DEA will hold those medical practitioners accountable who fail to comply with the Controlled Substance Act (CSA) in order to deter pharmaceuticals from being abused,” said Jacob D. Galvan, Acting Special Agent in Charge, DEA Seattle Field Division. 

“The Controlled Substances Act has requirements for medical professionals and pharmacies so that certain narcotic substances are carefully tracked,” said U.S. Attorney Nick Brown. “Those requirements are designed to allow DEA to monitor the distribution of these drugs to try to combat abuse and addiction and the harms that follow.”

The settlement with Lincoln Pharmacy states that during an inspection in June 2021, DEA found that in a variety of ways, Lincoln Pharmacy failed to appropriately track controlled substances coming to the pharmacy. For example: Lincoln Pharmacy failed to maintain records on substances such as oxycodone and hydrocodone between March 2020 and June 2021; Lincoln Pharmacy’s inventories of scheduled drugs were inadequate; the pharmacy failed to keep records of when and how much of certain scheduled drugs were delivered to the pharmacy; the pharmacy failed to secure some of the controlled substances; and the pharmacy failed to keep the ‘private key’ secure - something used to sign DEA orders.

Lincoln is paying the $80,000 settlement but does not admit any liability.

This is the third entity to settle administrative claims with the U.S. Attorney’s Office over administrative failure to follow the Controlled Substances Act.

In September 2021, JRK Pharma Inc d/b/a Edmonds Pharmacy settled allegations that between October 2019 and May 2021, it filled 347 prescriptions for controlled substances written by two practitioners who either did not have valid state licensed to practice medicine or did not have an active DEA license to prescribe controlled substances. Edmonds Pharmacy paid $20,000 to resolve the allegations and does not admit liability.

In August 2022, Dr. Akiko Kato, a naturopathic physician, signed a settlement stating that she prescribed controlled substances that were outside her naturopathic license and limitations under the CSA. Between October 2016 and October 2021, she wrote 644 prescriptions for substances such as Dextroamphetamine, Alprazolam, Clonazepam, Ketamine, and Phentermine. Dr. Kato was not authorized to prescribe such prescriptions. Dr. Kato paid a $37,500 settlement.

These cases were a result of a concerted focus of DEA to prevent pharmacies from filling prescriptions written by providers without prescribing authority for those substances. 

The DEA investigated these matters and the cases were resolved by Assistant United States Attorneys Matt Waldrop and Ashley Burns.

###

Download Press Release
###
Oxycodone
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

David F. Reames Special Agent in Charge - Seattle
@DEASeattleDiv
  • Facebook
  • X
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster